ClinicalTrials.gg
CompletedNCT05458128Updated Nov 13, 2026Results posted

A Long-Term Safety and Effectiveness Study to Evaluate Pitolisant in Adult Patients With Idiopathic Hypersomnia

A Phase 3 interventional study of Pitolisant in Idiopathic Hypersomnia and Excessive Daytime Sleepiness, sponsored by Harmony Biosciences Management, Inc.. Completed at 32 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Harmony Biosciences Management, Inc. (part of Harmony Biosciences Holdings, Inc.) · Phase 3, Interventional, and Treatment

Updated Nov 13, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
119
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies in Idiopathic Hypersomnia with a site in United States — 12 open to participants now, 13 under way, 4 of them phase 3. Idiopathic Hypersomnia · United States.

Enrollment
13th of 27
119 · median 100
Started
2022
with 3 others
Phase 3
6 of 30
2 open now
Registered
15th of 30
by date
Lead sponsor
3 of 30
Harmony Biosciences Management, Inc.

Among the 30 studies in Idiopathic Hypersomnia with a site in United States, this one is the 13th largest by enrollment of the 27 interventional ones that give a count, is one of 4 that started in 2022, is one of 6 in phase 3, and was the 15th registered.

Idiopathic Hypersomnia

53 studies on the registry are indexed under Idiopathic Hypersomnia; 24 are open to participants now.

Browse Idiopathic Hypersomnia studies →

Open to participants now

12 of the 30 studies in Idiopathic Hypersomnia with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 17 Idiopathic Hypersomnia studies recruiting now, 4 (24%) set no upper age limit and 12 (71%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Idiopathic Hypersomnia with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this study is to assess the long-term safety and effectiveness of pitolisant in patients with idiopathic hypersomnia (IH) who completed the Double-Blind Randomized Withdrawal Phase of study HBS-101-CL-010.

Read the detailed description

This is a Phase 3 open-label study to evaluate the long-term safety and effectiveness of pitolisant in adult patients with IH. Patients who complete the Double-Blind Randomized Withdrawal Phase of study HBS-101-CL-010 (i.e., completed the End-of-Treatment [EOT] Visit/Visit 5 in the HBS-101-CL-010 study) and who continue to meet eligibility criteria for study HBS-101-CL-011 are eligible for enrollment.

Enrolled patients will be dispensed open-label pitolisant and may be titrated up to a maximum dose of 35.6 mg, based on the Investigator's assessment of safety/tolerability and effectiveness, during a 3-week Titration Period (Day 1 to Day 21) in accordance with the schedule:

  • Week 1 (Day 1-7), 8.9 mg
  • Week 2 (Day 8-14), 17.8 mg
  • Week 3 (Day 15-21), 35.6 mg

The Long-Term Dosing Period will begin on Day 22 and will continue until the patient discontinues from the study or the Sponsor elects to terminate the study (i.e., End-of-Study [EOS]).

An on-site study visit will occur approximately 180 days after Visit 2 on Day 202 (Visit 3). On-site study visits will occur approximately every 6 months and telephone contacts (TCs) approximately every one month in between until the patient withdraws from the study or the study is terminated by the Sponsor. The dose of pitolisant may be adjusted (higher or lower) in increments of 4.45 mg starting at 8.9 mg up to 35.6 mg during the Long-Term Dosing Period based on Investigator assessment of safety/tolerability and effectiveness.

All patients will receive safety follow-up TCs from the study site 15 days and 30 days after their final dose of pitolisant, to assess for adverse events (AEs) and concomitant medication use.

03

Conditions studied

  • Idiopathic Hypersomnia
  • Excessive Daytime Sleepiness

Keywords

  • pitolisant
  • histamine
  • sleepiness
  • IH
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Is able to provide voluntary, .
  2. Completed the Double-Blind Randomized Withdrawal Phase (EOT/Visit 5) from the HBS-101-CL-010 study.
  3. A patient who is a female of must have a negative urine pregnancy test at the Screening Visit. A patient who is a female of child-bearing potential must agree to remain abstinent or use an effective method of non-hormonal to prevent pregnancy for the duration of the study and for 21 days after final dose of study drug.
  4. Must have a negative result on urine drug screen at the Screening Visit, except for medications that are prescribed by a healthcare provider for medical conditions.
  5. In the opinion of the Investigator, the patient is capable of understanding and complying with the protocol and administration of oral study drug.

Exclusion criteria

Exclusion Criteria:

  1. Does not agree to discontinue any prohibited medication or substances listed in the protocol.
  2. Is currently breastfeeding or planning to breastfeed over the course of the study. Lactating women must agree not to breastfeed for the duration of the study and for 21 days after final dose of study drug.
  3. Participation in an interventional research study with an medication or device, other than pitolisant, for the duration of the study.
  4. Has a diagnosis of end-stage renal disease (ESRD; estimated [eGFR] of \<15 mL/minute/1.73 m2) or severe hepatic impairment ( C).
  5. Is receiving or is unable to discontinue a medication known to prolong the .
  6. Has a significant risk of committing suicide or suicidality based on history; routine psychiatric examination; Investigator's judgment; or who has an answer of "yes" on any question other than questions 1 to 3 or "yes" on any question in the suicidal behavior section of the C-SSRS, Since Last Visit.
  7. Based on the judgment of the Investigator, is unsuitable for the study for any reason, including but not limited to an unstable or uncontrolled medical condition or one that might interfere with the conduct of the study, confound interpretation of study results, pose a health risk to the patient, or compromise the integrity of the study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
119 participants (actual)

Study arms

  • Other
    Pitolisant

    Week 1: 8.9 mg pitolisant administered once daily in the morning upon wakening; Week 2: 17.8 mg pitolisant administered once daily in the morning upon wakening; Weeks 3 through end of treatment: 17.8 mg to 35.6 mg pitolisant administered once daily in the morning upon wakening.

    Drug: Pitolisant

Interventions

  • Pitolisant 4.45 mg tablets Pitolisant 17.8 mg tablets

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAE)

    A TEAE was defined as any new adverse event or any worsening of a pre-existing condition that was reported after first dose of study drug and up to 30 days after the date of last dose of study drug.

    Time frame: Up to approximately 3 years

  2. Change From Baseline in Epworth Sleepiness Scale (ESS) Score

    The Epworth Sleepiness Scale (ESS) is an 8-item, 4-point rating scale that asks participants to rate the likelihood of falling asleep over the past week. The rating scale ranges from 0 (no chance of dozing) to 3 (high chance of dozing). The total score is calculated by summing the item level ratings. Total scores range from 0 to 24. Higher scores represent more severe daytime sleepiness.

    Time frame: Baseline, Week 4 and Months 7, 13, 19, 25, 31

Secondary outcomes

  1. Change From Baseline in Idiopathic Hypersomnia Severity Scale (IHSS) Score

    The Idiopathic Hypersomnia Severity Scale (IHSS) is a self-administered questionnaire with a total of 14 items that assess long sleep duration and sleep inertia (5 items), daytime functioning (7 items), and napping (2 items). All items are scored from 0 to 3 or from 0 to 4. The total score is a sum of the item scores. The total score ranges from 0 to 50. A higher score indicates more severe and frequent symptoms.

    Time frame: Baseline, Week 4 and Months 7, 13, 19, 25, 31

  2. Change From Baseline in Clinical Global Impression of Severity (CGI-S) Scale Score for IH (CGI-S [IH])

    The CGI-S (IH) is an investigator-rated assessment. It uses a single-item, 5-point Likert-type rating scale that ranges from: none (1); mild (2); moderate (3); severe (4); very severe (5). An assessment of less severe symptoms represents an improvement in the investigator's perception of the participant's overall clinical status related to idiopathic hypersomnia and is reflected by a decrease in score.

    Time frame: Baseline, Week 4 and Months 7, 13, 19, 25, 31

  3. Change From Baseline in Patient Global Impression of Severity (PGI-S) Scale Score for Excessive Daytime Sleepiness (EDS) (PGI-S [EDS])

    The Patient Global Impression of Severity for Excessive Daytime Sleepiness (PGI-S \[EDS\]) asks participants to rate their overall impression of the severity of their EDS over the past 7 days on a 5-point verbal rating scale ranging from "none" to "very severe". Scores are: 1=None, 2=Mild, 3=Moderate, 4=Severe, and 5=Very Severe.

    Time frame: Baseline, Week 4 and Months 7, 13, 19, 25, 31

  4. Change From Baseline in Functional Outcomes of Sleep Questionnaire 10-item Version (FOSQ-10) Score

    The Functional Outcomes of Sleep Questionnaire 10-Item Version (FOSQ-10) consists of 10 items assessing the impact of sleepiness on daily functioning across 5 domains: vigilance, general productivity, social outcomes, intimacy, and activity level. Each item is rated on a scale of 0 (activity not performed for other reasons), 1 (extreme difficulty), 2 (moderate difficulty), 3 (a little difficulty), and 4 (no difficulty). The FOSQ-10 total score is calculated by multiplying the mean of the subscale scores by five, with final scores ranging from 5-20. Higher scores correspond to less impairment/symptomatic severity.

    Time frame: Baseline, Week 4 and Months 7, 13, 19, 25, 31

  5. Change From Baseline in Patient-Reported Outcomes Measurement Information System Sleep-Related Impairment Item Bank v1.0-Short Form 8a (PROMIS-SRI SF 8a) Total T-Score

    The PROMIS-SRI SF 8a is a self-report measure that includes 8 questions designed to assess a participant's perceptions of their waking alertness, sleepiness, and tiredness during usual waking hours, and the perceived functional impairments during wakefulness associated with sleep problems or impaired alertness over the past week. Responses are rated using a 5-point scale, with responses ranging from 1 to 5. Raw scores are converted to a T-score using the conversion table from the PROMIS-SRI Scoring Manual. Raw score ranges from 8 to 40. T-score ranges from 30 to 80.1. Higher scores represent greater impairment. HealthMeasures reports that PROMIS-SRI SF 8a T-score mean is 50 with a standard deviation of 10 in the general population.

    Time frame: Baseline, Week 4 and Months 7, 13, 19, 25, 31

  6. Change From Baseline in Sleep Inertia Questionnaire (SIQ) Score

    The Sleep Inertia Questionnaire (SIQ) score is the sum of 21 questions that assess sleep inertia. Each question is rated on a scale of 1 to 5, where: 1=not at all; 2=a little; 3=somewhat; 4=often; 5=all the time. Total scores range from 21 to 105. Higher scores represent greater sleep inertia.

    Time frame: Baseline, Week 4 and Months 7, 13, 19, 25, 31

07

Results

Posted Nov 13, 2026

Participant flow

Participant flow — Overall Study
MilestonePitolisant
Started119
Received at least one dose of study treatment119
Completed62
Not completed57
Withdrew: Withdrawal by subject19
Withdrew: Lack of efficacy13
Withdrew: Lost to follow-up7
Withdrew: Adverse event6
Withdrew: Other : not specified6
Withdrew: Withdrawal by subject4
Withdrew: Non-compliance with study drug1
Withdrew: Protocol violation1

Outcome measures

PrimaryNumber of Participants With Treatment Emergent Adverse Events (TEAE)

A TEAE was defined as any new adverse event or any worsening of a pre-existing condition that was reported after first dose of study drug and up to 30 days after the date of last dose of study drug.

Time frame:
Up to approximately 3 years
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAE)
ParticipantsPitolisant
Number of Participants With Treatment Emergent Adverse Events (TEAE)104
PrimaryChange From Baseline in Epworth Sleepiness Scale (ESS) Score

The Epworth Sleepiness Scale (ESS) is an 8-item, 4-point rating scale that asks participants to rate the likelihood of falling asleep over the past week. The rating scale ranges from 0 (no chance of dozing) to 3 (high chance of dozing). The total score is calculated by summing the item level ratings. Total scores range from 0 to 24. Higher scores represent more severe daytime sleepiness.

Time frame:
Baseline, Week 4 and Months 7, 13, 19, 25, 31
Reported as:
Mean · score on a scale
Change From Baseline in Epworth Sleepiness Scale (ESS) Score
score on a scalePitolisant
Week 4-3.7 ± 4.53
Month 7-3.1 ± 5.13
Month 13-3.4 ± 4.74
Month 19-3.0 ± 5.83
Month 25-4.0 ± 5.50
Month 31-3.3 ± 3.44
SecondaryChange From Baseline in Idiopathic Hypersomnia Severity Scale (IHSS) Score

The Idiopathic Hypersomnia Severity Scale (IHSS) is a self-administered questionnaire with a total of 14 items that assess long sleep duration and sleep inertia (5 items), daytime functioning (7 items), and napping (2 items). All items are scored from 0 to 3 or from 0 to 4. The total score is a sum of the item scores. The total score ranges from 0 to 50. A higher score indicates more severe and frequent symptoms.

Time frame:
Baseline, Week 4 and Months 7, 13, 19, 25, 31
Reported as:
Mean · score on a scale
Change From Baseline in Idiopathic Hypersomnia Severity Scale (IHSS) Score
score on a scalePitolisant
Week 4-6.4 ± 7.96
Month 7-5.7 ± 8.17
Month 13-6.4 ± 8.22
Month 19-6.3 ± 9.14
Month 25-6.0 ± 10.81
Month 31-3.8 ± 3.82
SecondaryChange From Baseline in Clinical Global Impression of Severity (CGI-S) Scale Score for IH (CGI-S [IH])

The CGI-S (IH) is an investigator-rated assessment. It uses a single-item, 5-point Likert-type rating scale that ranges from: none (1); mild (2); moderate (3); severe (4); very severe (5). An assessment of less severe symptoms represents an improvement in the investigator's perception of the participant's overall clinical status related to idiopathic hypersomnia and is reflected by a decrease in score.

Time frame:
Baseline, Week 4 and Months 7, 13, 19, 25, 31
Reported as:
Mean · score on a scale
Change From Baseline in Clinical Global Impression of Severity (CGI-S) Scale Score for IH (CGI-S [IH])
score on a scalePitolisant
Week 4-0.7 ± 1.07
Month 7-0.7 ± 1.06
Month 13-0.9 ± 0.99
Month 19-0.8 ± 1.19
Month 25-0.9 ± 1.11
Month 31-0.7 ± 0.52
SecondaryChange From Baseline in Patient Global Impression of Severity (PGI-S) Scale Score for Excessive Daytime Sleepiness (EDS) (PGI-S [EDS])

The Patient Global Impression of Severity for Excessive Daytime Sleepiness (PGI-S \[EDS\]) asks participants to rate their overall impression of the severity of their EDS over the past 7 days on a 5-point verbal rating scale ranging from "none" to "very severe". Scores are: 1=None, 2=Mild, 3=Moderate, 4=Severe, and 5=Very Severe.

Time frame:
Baseline, Week 4 and Months 7, 13, 19, 25, 31
Reported as:
Mean · score on a scale
Change From Baseline in Patient Global Impression of Severity (PGI-S) Scale Score for Excessive Daytime Sleepiness (EDS) (PGI-S [EDS])
score on a scalePitolisant
Week 4-0.7 ± 1.17
Month 7-0.7 ± 1.14
Month 13-0.7 ± 1.07
Month 19-0.6 ± 1.23
Month 25-0.7 ± 1.30
Month 31-0.5 ± 0.84
SecondaryChange From Baseline in Functional Outcomes of Sleep Questionnaire 10-item Version (FOSQ-10) Score

The Functional Outcomes of Sleep Questionnaire 10-Item Version (FOSQ-10) consists of 10 items assessing the impact of sleepiness on daily functioning across 5 domains: vigilance, general productivity, social outcomes, intimacy, and activity level. Each item is rated on a scale of 0 (activity not performed for other reasons), 1 (extreme difficulty), 2 (moderate difficulty), 3 (a little difficulty), and 4 (no difficulty). The FOSQ-10 total score is calculated by multiplying the mean of the subscale scores by five, with final scores ranging from 5-20. Higher scores correspond to less impairment/symptomatic severity.

Time frame:
Baseline, Week 4 and Months 7, 13, 19, 25, 31
Reported as:
Mean · score on a scale
Change From Baseline in Functional Outcomes of Sleep Questionnaire 10-item Version (FOSQ-10) Score
score on a scalePitolisant
Week 41.685 ± 2.6414
Month 71.801 ± 3.4167
Month 132.054 ± 3.3404
Month 192.054 ± 3.7440
Month 252.433 ± 3.6093
Month 312.813 ± 3.1331
SecondaryChange From Baseline in Patient-Reported Outcomes Measurement Information System Sleep-Related Impairment Item Bank v1.0-Short Form 8a (PROMIS-SRI SF 8a) Total T-Score

The PROMIS-SRI SF 8a is a self-report measure that includes 8 questions designed to assess a participant's perceptions of their waking alertness, sleepiness, and tiredness during usual waking hours, and the perceived functional impairments during wakefulness associated with sleep problems or impaired alertness over the past week. Responses are rated using a 5-point scale, with responses ranging from 1 to 5. Raw scores are converted to a T-score using the conversion table from the PROMIS-SRI Scoring Manual. Raw score ranges from 8 to 40. T-score ranges from 30 to 80.1. Higher scores represent greater impairment. HealthMeasures reports that PROMIS-SRI SF 8a T-score mean is 50 with a standard deviation of 10 in the general population.

Time frame:
Baseline, Week 4 and Months 7, 13, 19, 25, 31
Reported as:
Mean · T-score
Change From Baseline in Patient-Reported Outcomes Measurement Information System Sleep-Related Impairment Item Bank v1.0-Short Form 8a (PROMIS-SRI SF 8a) Total T-Score
T-scorePitolisant
Week 4-4.92 ± 7.124
Month 7-3.75 ± 8.408
Month 13-4.48 ± 7.778
Month 19-4.90 ± 8.423
Month 25-5.20 ± 9.170
Month 31-3.48 ± 5.232
SecondaryChange From Baseline in Sleep Inertia Questionnaire (SIQ) Score

The Sleep Inertia Questionnaire (SIQ) score is the sum of 21 questions that assess sleep inertia. Each question is rated on a scale of 1 to 5, where: 1=not at all; 2=a little; 3=somewhat; 4=often; 5=all the time. Total scores range from 21 to 105. Higher scores represent greater sleep inertia.

Time frame:
Baseline, Week 4 and Months 7, 13, 19, 25, 31
Reported as:
Mean · score on a scale
Change From Baseline in Sleep Inertia Questionnaire (SIQ) Score
score on a scalePitolisant
Week 4-9.18 ± 15.74
Month 7-8.4 ± 16.85
Month 13-7.7 ± 16.92
Month 19-8.0 ± 19.31
Month 25-8.1 ± 22.77
Month 31-8.8 ± 9.33

Adverse events

Collected over Up to approximately 3 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pitolisant0/119 (0%)6/119 (5%)84/119 (70.6%)
Most frequent serious events
Most frequent serious events
EventPitolisant
AppendicitisInfections and infestations1/119
Breast cellulitisInfections and infestations1/119
CellulitisInfections and infestations1/119
Atrial fibrillationCardiac disorders1/119
Lower limb fractureInjury, poisoning and procedural complications1/119
HypoaesthesiaNervous system disorders1/119
Transient ischaemic attackNervous system disorders1/119
DepressionPsychiatric disorders1/119
Most frequent other events
Showing 10 of 15
Most frequent other events
EventPitolisant
COVID-19Infections and infestations27/119
Upper respiratory tract infectionInfections and infestations20/119
NasopharyngitisInfections and infestations16/119
InsomniaPsychiatric disorders16/119
HeadacheNervous system disorders14/119
Urinary tract infectionInfections and infestations12/119
SinusitisInfections and infestations9/119
NauseaGastrointestinal disorders8/119
Pharyngitis streptococcalInfections and infestations7/119
BronchitisInfections and infestations6/119

Baseline characteristics

Age, Continuous
Age, Continuous(years)Pitolisant
Mean40.1 ± 11.96
Sex: Female, Male
Sex: Female, Male(Participants)Pitolisant
Female95
Male24
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Pitolisant
Hispanic or Latino8
Not Hispanic or Latino111
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Pitolisant
American Indian or Alaska Native0
Asian4
Native Hawaiian or Other Pacific Islander0
Black or African American7
White106
More than one race0
Unknown or Not Reported2
08

Study locations

32 sites
  • Cedars-Sinai Medical Towers
    Los Angeles, California 90048, United States
  • Sleep Medicine Specialists of California
    San Ramon, California 94583, United States
  • Meris Clinical Research
    Brandon, Florida 33511, United States
  • St. Francis Medical Institute
    Clearwater, Florida 33765, United States
  • Florida Pediatric Research Institute
    Winter Park, Florida 32789, United States
  • Neurotrials Research Inc.
    Atlanta, Georgia 30328, United States
  • NorthShore University Health System
    Glenview, Illinois 60026, United States
  • OSF HealthCare Saint Francis Medical Center
    Peoria, Illinois 61637, United States
  • Western Michigan University Homer Stryker MD School of Medicine
    Kalamazoo, Michigan 49008, United States
  • Clinical Neurophysiology Services
    Sterling Heights, Michigan 48314, United States
  • St. Luke's Sleep Medicine and Research Center
    Chesterfield, Missouri 63017, United States
  • Clayton Sleep Institute
    St Louis, Missouri 63123, United States
  • Great Plains Health
    North Platte, Nebraska 69101, United States
  • Sleep Dynamics
    Neptune City, New Jersey 07753, United States
  • Northwell Health
    New Hyde Park, New York 11042, United States
  • Duke University School of Medicine
    Durham, North Carolina 27705, United States
  • Clinical Research of Gastonia
    Gastonia, North Carolina 28054, United States
  • ARSM Research
    Huntersville, North Carolina 28078, United States
  • NeuroScience Research Center, LLC
    Canton, Ohio 44718, United States
  • Intrepid Research, LLC
    Cincinnati, Ohio 45245, United States
  • Ohio Sleep Medicine and Neuroscience Institue
    Dublin, Ohio 43017, United States
  • North Star Medical Research
    Middleburg, Ohio 44130, United States
  • Abington Neurological Associates
    Willow Grove, Pennsylvania 19090, United States
  • Respiratory Specialists
    Wyomissing, Pennsylvania 19610, United States
  • Bogan Sleep Consultants
    Columbia, South Carolina 29201, United States
  • Lowcountry Lung Critical Care
    North Charleston, South Carolina 29406, United States
  • Neurology Clinic, P.C.
    Cordova, Tennessee 38018, United States
  • FutureSearch Trials of Neurology LP
    Austin, Texas 78731, United States
  • Central Texas Neurology Consultants, PA
    Round Rock, Texas 78681, United States
  • Comprehensive Sleep Medicine Associates
    Sugar Land, Texas 77478, United States
  • Northwest Houston Neurology and Sleep
    Tomball, Texas 77375, United States
  • University of Wisconsin-Madison
    Madison, Wisconsin 53719, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2022 to primary completion in Oct 2025, 37 months.

Results were first posted in Nov 2026, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2022
First posted
Jul 14, 2022
StartActual
Aug 19, 2022
Primary completionActual
Oct 1, 2025
CompletionActual
Oct 1, 2025
Results first posted
Nov 13, 2026
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 13, 2026
Primary outcomes
2 added, 2 removed
What changed in the outcomes
  • AddedNumber of Participants With Treatment Emergent Adverse Events (TEAE)Time frame: Up to approximately 3 years
  • AddedChange From Baseline in Epworth Sleepiness Scale (ESS) ScoreTime frame: Baseline, Week 4 and Months 7, 13, 19, 25, 31
  • RemovedSafety and tolerability of pitolisantTime frame: Up to approximately 3 years
  • RemovedExcessive daytime sleepinessTime frame: Up to approximately 3 years
Nov 13, 2026
Documents
Secondary outcomes
6 added, 6 removed
What changed in the outcomes
  • AddedChange From Baseline in Idiopathic Hypersomnia Severity Scale (IHSS) ScoreTime frame: Baseline, Week 4 and Months 7, 13, 19, 25, 31
  • AddedChange From Baseline in Clinical Global Impression of Severity (CGI-S) Scale Score for IH (CGI-S [IH])Time frame: Baseline, Week 4 and Months 7, 13, 19, 25, 31
  • AddedChange From Baseline in Patient Global Impression of Severity (PGI-S) Scale Score for Excessive Daytime Sleepiness (EDS) (PGI-S [EDS])Time frame: Baseline, Week 4 and Months 7, 13, 19, 25, 31
  • AddedChange From Baseline in Functional Outcomes of Sleep Questionnaire 10-item Version (FOSQ-10) ScoreTime frame: Baseline, Week 4 and Months 7, 13, 19, 25, 31
  • AddedChange From Baseline in Patient-Reported Outcomes Measurement Information System Sleep-Related Impairment Item Bank v1.0-Short Form 8a (PROMIS-SRI SF 8a) Total T-ScoreTime frame: Baseline, Week 4 and Months 7, 13, 19, 25, 31
  • AddedChange From Baseline in Sleep Inertia Questionnaire (SIQ) ScoreTime frame: Baseline, Week 4 and Months 7, 13, 19, 25, 31
  • RemovedSymptoms of idiopathic hypersomniaTime frame: Up to approximately 3 years
  • RemovedSymptoms of idiopathic hypersomniaTime frame: Up to approximately 3 years
  • RemovedSymptoms of idiopathic hypersomniaTime frame: Up to approximately 3 years
  • RemovedFunctional outcomes of sleepTime frame: Up to approximately 3 years
  • RemovedSleep related impairments during wakefulnessTime frame: Up to approximately 3 years
  • RemovedSleep inertiaTime frame: Up to approximately 3 years
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Results posted
    Primary outcomes 2 added, 2 removed
    What changed in the outcomes
    • AddedNumber of Participants With Treatment Emergent Adverse Events (TEAE)Time frame: Up to approximately 3 years
    • AddedChange From Baseline in Epworth Sleepiness Scale (ESS) ScoreTime frame: Baseline, Week 4 and Months 7, 13, 19, 25, 31
    • RemovedSafety and tolerability of pitolisantTime frame: Up to approximately 3 years
    • RemovedExcessive daytime sleepinessTime frame: Up to approximately 3 years
    Secondary outcomes 6 added, 6 removed
    What changed in the outcomes
    • AddedChange From Baseline in Idiopathic Hypersomnia Severity Scale (IHSS) ScoreTime frame: Baseline, Week 4 and Months 7, 13, 19, 25, 31
    • AddedChange From Baseline in Clinical Global Impression of Severity (CGI-S) Scale Score for IH (CGI-S [IH])Time frame: Baseline, Week 4 and Months 7, 13, 19, 25, 31
    • AddedChange From Baseline in Patient Global Impression of Severity (PGI-S) Scale Score for Excessive Daytime Sleepiness (EDS) (PGI-S [EDS])Time frame: Baseline, Week 4 and Months 7, 13, 19, 25, 31
    • AddedChange From Baseline in Functional Outcomes of Sleep Questionnaire 10-item Version (FOSQ-10) ScoreTime frame: Baseline, Week 4 and Months 7, 13, 19, 25, 31
    • AddedChange From Baseline in Patient-Reported Outcomes Measurement Information System Sleep-Related Impairment Item Bank v1.0-Short Form 8a (PROMIS-SRI SF 8a) Total T-ScoreTime frame: Baseline, Week 4 and Months 7, 13, 19, 25, 31
    • AddedChange From Baseline in Sleep Inertia Questionnaire (SIQ) ScoreTime frame: Baseline, Week 4 and Months 7, 13, 19, 25, 31
    • RemovedSymptoms of idiopathic hypersomniaTime frame: Up to approximately 3 years
    • RemovedSymptoms of idiopathic hypersomniaTime frame: Up to approximately 3 years
    • RemovedSymptoms of idiopathic hypersomniaTime frame: Up to approximately 3 years
    • RemovedFunctional outcomes of sleepTime frame: Up to approximately 3 years
    • RemovedSleep related impairments during wakefulnessTime frame: Up to approximately 3 years
    • RemovedSleep inertiaTime frame: Up to approximately 3 years
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05458128
Responsible party
Sponsor
First posted
Jul 14, 2022
Start date
Aug 19, 2022
Primary completion
Oct 1, 2025
Completion
Oct 1, 2025
Results posted
Nov 13, 2026
Last update
Nov 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pitolisant

Start the discussion